Graph AI, a California-based startup that builds AI software for pharmacovigilance and patient safety teams, has raised US$13.3 million in a series A round led by Insight Partners, with existing investor Bessemer Venture Partners participating.

The company said it will use the funding to expand in the US and Europe and accelerate product development. The round follows a US$3 million seed round from Bessemer.

Graph AI said its platform automates pharmacovigilance and patient safety workflows.

In live deployments, it said the software cut case-processing time from more than three hours to under 10 minutes. The company added that the software lowered operating costs by up to 66%.

Graph AI also said it has signed pharmaceutical and biotech customers across North America and other markets, and formed design partnerships for upcoming modules.

The funding comes as the European Medicines Agency and the US Food and Drug Administration have set common principles for AI in medicine development. Vendors such as IQVIA also offer drug safety and pharmacovigilance software.

🔗 Source: YourStory